Experience in the Use of Tofacitinib in the Treatment of Ulcerative Colitis in Two Pediatric Patients: Two Case Reports
DOI:
https://doi.org/10.52787/agl.v53i4.331Keywords:
Ulcerative colitis, tofacitinib, adolescence, pediatrics, Janus kinase, biological therapyAbstract
Introduction. In this report, the experience using tofacitinib in two pediatric patients diagnosed with ulcerative colitis at the International Hospital of Colombia is described. A review of the current state of the art is also carried out.
Cases. Both patients had already undergone conventional management without an adequate response for almost two years. In case 1, clinical remission was achieved one month after initiating sustained treatment with tofacitinib. In case 2, clinical and endoscopic remissions were achieved two months after initiating treatment.
Discussion. Studies have demonstrated its efficacy as induction and maintenance therapy for moderate to severe active ulcerative colitis, with an acceptable safety profile. However, information about the use of tofacitinib within the treatment arsenal is limited in the pediatric age group.
Conclusion. Tofacitinib is a promising alternative for the treatment of ulcerative colitis with no response or loss of response to conventional treatment. We present the experience of two adolescent patients in whom clinical remission of the disease was achieved earlier than expected, also documenting endoscopic and histologic remission in one of them.
References
-1. Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Algoritmos diagnósticos y terapéuticos de la colitis ulcerosa. Dtsch Arztebl Int. 2020;117(33-34):564-74. DOI: 10.3238/arztebl.2020.0564
-2. Juliao F, Grillo CF, Alfaro I, et al. Update of the PANCCO clinical practice guidelines for the treatment of ulcerative colitis in the adult population. Rev Gastroenterol Mex (Engl Ed). 2022;87(3):342-61. DOI: 10.1016/j.rgmxen.2022.04.006
-3. Panés, J, Gisber JP. Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterol Hepatol. 2019;42(6):403-12. DOI: 10.1016/j.gastrohep.2019.0
-4. Moore H, Dubes L, Fusillo S, Baldassano R, Stein R. Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease. JPGN. 2021;73:e57-e62.
-5. Stallard L, Hussey S. Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor. Front Pediatr. 2021;9:678132. DOI: 10.3389/fped.2021.678132
-6. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):292-310. DOI: 10.1097/MPG.0000000000002036
-7. Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, et al. Maintenance of Remission with Tofacitinib Therapy in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2022;20(1):116-25. DOI.org/10.1016/j.cgh.2020.10.004
-8. Quera R, Flores L, Núñez P, Ibáñez P. Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos. Rev. Méd. 2020;148(7):1039-43.
-9. Del Brío R. Nuevas terapias en enfermedad inflamatoria intestinal. Canarias Pediátrica. 2022;46(2): 206-12.
-10. Sedano R, Ma C, Jairath V, Feagan BG. Janus Kinase Inhibitors for the Management of Patients with Inflammatory Bowel Disease. Gastroenterol Hepatol. 2022;18:14-27.
-11. López A, Esplugues JV, Domènech E. Farmacología y seguridad de tofacitinib en colitis ulcerosa. Gastroenterol Hepatol. 2021;44:39-48.
-12. Sandborn W, Su C, Sands B, D’Haens G, Vermeire S, Schreiber S, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Eng J Med. 2017;376(18):1723-36. DOI: 10.1056/nejmoa1606910
-13. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179-91.e6. DOI: 10.1016/j.cgh.2020.01.008
-14. Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020; 52(3):268-73. DOI: 10.1016/j.dld.2019.10.003.
-15. Parra V, Frías JS, Márquez JR, Juliao F, Galindo P, Cuadros C, et al. Tofacitinib en el tratamiento de la colitis ulcerosa de moderada a grave en Colombia: experiencia en mundo real. Gastroenterol Hepatol. 2023;46(7):512-21. DOI: 10.1016/j.gastrohep.2022.10.020
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Karen Velásquez Vanegas, Carlos Augusto Cuadros Mendoza, María José Daniels García, Viviana Parra Izquierdo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
